Summary by Futu AI
Clover Biopharmaceuticals Limited (the “Company”) informed its shareholders on 23 February 2024 that it has made new arrangements for the electronic publication of the Company's communications pursuant to Section 2.07A of the Securities Listing Rules of the Hong Kong Stock Exchange Limited and Articles of Association. The move is to support environmental protection and improve the efficiency of communication with shareholders, and is in line with the paperless listing mechanism in place from 31 December 2023. Corporate communications include Directors' Reports, Annual Accounts, Audit Reports, Interim Reports, Notice of Meeting, Listing Documents, Circulars and Appointment Forms, etc. The Company encourages shareholders to obtain this information via the Company's website or the HKEX, rather than to receive the printed version by mail. Shareholders may...Show More